Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
NEW QUEBEC GRAPHITE TRANSFORMATION STUDY FOR LAC CARHEIL PROJECT DELIVERS IMPRESSIVE ECONOMIC RESULTS
Canada One Announces 2026 Two-Phase Exploration Program to Advance High-Priority Porphyry Targets at Copper Dome
